Knopp Biosciences: Dexpramipexole targets eosinophilic inflammation

Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases. Asthma affects more than 300 million people worldwide, and is the most common noncommunicable disease among children. No cure exists for chronic asthma; most patients … Continued

Basalt to Acquire Xpress Natural Gas

NEW YORK–(BUSINESS WIRE)–Feb 1, 2021– Basalt Infrastructure Partners LLC (“Basalt”) announced today that the third flagship Basalt fund (“Basalt III”) has entered into a definitive agreement to acquire Xpress Natural Gas (“XNG” or the “Company”). XNG is a fully integrated … Continued

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Jan. 14, 2021 11:00 UTC Primary endpoint was achieved, with dexpramipexole demonstrating a statistically significant reduction in blood eosinophil count over 12 weeks Reduction in blood eosinophil count correlated with clinically important improvement in lung function PITTSBURGH–(BUSINESS WIRE)– Knopp Biosciences LLC today … Continued